妊娠期接种BNT162b2 mRNA新冠疫苗的短期结局
这项观察性病例对照研究比较了妊娠期接种两剂BNT162b2疫苗的孕妇与年龄匹配的非妊娠接种女性的免疫原性、反应原性及产科结局。孕妇接种后局部和全身不良反应谱与非妊娠女性总体相似,未见安全信号;孕妇SARS-CoV-2 IgG水平显著低于非妊娠女性,但所有样本均为阳性。已分娩的57例孕妇中无早产、无胎儿或新生儿死亡。
要点
- 孕妇接种BNT162b2后不良反应谱与非妊娠女性相似,未见新的安全信号。
- 孕妇接种后SARS-CoV-2 IgG均为阳性,但信号/临界值比值显著低于非妊娠女性。
- 已分娩的57例中无早产(<37周)、无胎儿或新生儿死亡,短期产科结局良好。
关键影像表现/征象
- 孕妇接种后皮疹、发热和严重疲劳的发生率与非妊娠女性相当。
- 孕妇接种后肌痛、关节痛和头痛在各剂次后均显著更少见。
- 孕妇第一剂后局部疼痛或肿胀、第二剂后腋窝淋巴结病显著更少见,第二剂后感觉异常显著更常见。
- 孕妇各孕期接种的不良反应发生率无显著差异,例外为第三孕期接种第一剂后局部疼痛/肿胀显著更少、第三孕期接种第二剂后子宫收缩显著更常见。
- 产科并发症发生率很低:子宫收缩第一剂后1.3%、第二剂后6.4%;阴道出血第一剂后0.3%、第二剂后1.5%;胎膜早破第一剂后0%、第二剂后0.8%。
诊断标准与关键数值
- 两组所有血清样本SARS-CoV-2 IgG均为阳性。
- 孕妇组血清SARS-CoV-2 IgG信号/临界值比值显著低于非妊娠组(27.03 vs 34.35,P < 0.001)。
- 已分娩的57例孕妇中,分娩中位孕周为39.5周(四分位距38.7–40.0周),无<37周早产、无胎儿或新生儿死亡,2例(3.5%)因呼吸支持入住新生儿重症监护室。
临床应用与阅片要点
- 孕妇接种BNT162b2后不良反应谱与非妊娠女性总体相似,阅片或临床咨询时可据此告知局部疼痛/肿胀、腋窝淋巴结病等反应并非孕妇特有。
- 孕妇接种后IgG水平虽低于非妊娠女性但仍全部阳性,解读抗体检测结果时不应因孕妇抗体滴度较低而误判为无免疫应答。
- 第三孕期接种第二剂后子宫收缩报告率相对较高(6.4%),临床需结合症状鉴别,但整体产科并发症发生率很低。
局限性
- 本研究为观察性病例对照设计,非随机对照试验。
- 已分娩并完成第二份问卷的孕妇仅57例,产科和新生儿结局样本量有限。
- 不良反应和产科结局依赖参与者自填数字问卷,可能存在报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the immunogenicity and reactogenicity of the Pfizer/BioNTech BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine among pregnant women compared with non-pregnant women, and to evaluate obstetric outcome following vaccination.
METHODS: This was an observational case-control study of pregnant women who were vaccinated with a two-dose regimen of the BNT162b2 vaccine during gestation between January and February 2021 (study group) and age-matched non-pregnant women who received the vaccine during the same time period (control group). Participants received a digital questionnaire 1-4 weeks after the second dose and were asked to provide information regarding demographics, medication, medical history, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, timing of COVID-19 vaccine doses and side effects after each vaccine dose. A second digital questionnaire, regarding current pregnancy and delivery outcomes, was sent to patients in the study group after the calculated due date. All recruited women were offered a serology blood test for SARS-CoV-2 immunoglobulin G (IgG) following the second vaccination dose and SARS-CoV-2 IgG levels were compared between the two groups.
RESULTS: Of 539 pregnant women who were recruited after completion of the two-dose regimen of the vaccine, 390 returned the digital questionnaire and were included in the study group and compared to 260 age-matched non-pregnant vaccinated women. The rates of rash, fever and severe fatigue following vaccination among pregnant women were comparable to those in non-pregnant women. Myalgia, arthralgia and headache were significantly less common among pregnant women after each dose, local pain or swelling and axillary lymphadenopathy were significantly less common among pregnant women after the first and second doses, respectively, while paresthesia was significantly more common among the pregnant population after the second dose. Among pregnant women, there were no significant differences in the rates of side effects according to whether the vaccine was administered during the first, second or third trimester of pregnancy, except for local pain/swelling, which was significantly less common after the first dose when administered during the third trimester, and uterine contractions, which were significantly more common after the second dose when administered during the third trimester. The rates of obstetric complications, including uterine contractions (1.3% after the first dose and 6.4% after the second dose), vaginal bleeding (0.3% after the first dose and 1.5% after the second dose) and prelabor rupture of membranes (0% after the first dose and 0.8% after the second dose), were very low following vaccination. All serum samples in both groups were positive for SARS-CoV-2 IgG. However, pregnant women had significantly lower serum SARS-CoV-2 IgG levels compared to non-pregnant women (signal-to-cut-off ratio, 27.03 vs 34.35, respectively; P < 0.001). Among the 57 pregnant women who delivered during the study period and who completed the second questionnaire, median gestational age at delivery was 39.5 (interquartile range, 38.7-40.0) weeks, with no cases of preterm birth < 37 weeks, no cases of fetal or neonatal death and two (3.5%) cases of admission to the neonatal intensive care unit for respiratory support.
CONCLUSIONS: The adverse-effect profile and short-term obstetric and neonatal outcomes among pregnant women who were vaccinated with the BNT162b2 vaccine at any stage of pregnancy do not indicate any safety concerns. The vaccine is effective in generating a humoral immune response in pregnant women, although SARS-CoV-2 IgG levels were lower than those observed in non-pregnant vaccinated women. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bookstein Peretz S, Regev N, Novick L, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021. PMID: 34198360. doi:10.1002/uog.23729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。